Because carbasalate calcium combines high aqueous solubility with an acetylsalicylic acid–related hydrolysis pathway, direct compression tablet manufacture is limited to formulations with a controlled moisture budget. The API fraction in immediate-release tablet cores is typically maintained between 50 and 80 wt%, with microcrystalline cellulose and pregelatinized starch as diluents at 10–40 wt%, crospovidone as disintegrant at 2–6 wt%, and magnesium stearate as lubricant at 0.5–1.5 wt%, balanced to 100 wt%; a 300 mg carbasalate calcium core is therefore compressed at a target weight of 375–600 mg. Compliance for blend uniformity and release is anchored to USP <905>, Ph. Eur. 2.9.40, USP <711>, and Ph. Eur. 2.9.3, while elemental impurities and residual solvents are controlled under ICH Q3D and ICH Q3C. Production-scale observations on rotary presses such as the Fette 102i or Korsch XL 400 indicate that granulation-free direct compression is feasible only when the API bulk density exceeds 0.40 g/cm³ and the Hausner ratio remains below 1.30; otherwise precompression force must be raised from 5–10 kN to 12–18 kN, and capping defects increase when main compression force exceeds 24 kN. Standard runs target tablet hardness between 70 and 120 N and friability below 1.0 %. The tablet cores are film-coated with hydroxypropylmethylcellulose-based systems that introduce no more than 2–3 wt% additional moisture load, producing immediate-release film-coated tablets at 300 mg, 600 mg, or 1000 mg labels for oral antipyretic and anti-inflammatory use.

What Controls Fill-Weight Uniformity in Low-Dose Carbasalate Calcium Capsule Blends?

Capsule filling lines handling carbasalate calcium at doses below 100 mg are more sensitive to blend stratification than tablet presses because the encapsulation machine transfers material through a rotating dosing disc and tamping pins; batch records therefore control bulk density between 0.45 and 0.65 g/cm³ and require a Hausner ratio below 1.30. The dry-blend formula for hard gelatin or HPMC capsules contains 35–65 wt% carbasalate calcium, 25–50 wt% lactose monohydrate or mannitol, 2–4 wt% croscarmellose sodium, 0.2–0.8 wt% fumed silica, and 0.5–1.0 wt% magnesium stearate, balanced to 100 wt%; when the API fraction exceeds 65 wt%, the mix is wet-granulated before encapsulation to prevent powder flooding. Uniformity of dosage units is tested according to USP <905> and Ph. Eur. 2.9.40, dissolution according to USP <711> or Ph. Eur. 2.9.3, and residual solvents under ICH Q3C. On a Bosch GKF 2600 or Zanasi 40E, fill-weight variation is maintained within ±5 % of target by adjusting tamping pin depth to 2–4 mm and dosing-disc speed to 50–80 rpm; empty capsules are polished and checked for closures before metal detection. Hygroscopic excipients are limited because the acetylsalicylic ester group hydrolyzes when capsule moisture exceeds 2.0 %. Filled capsules are sealed into PVC/PVDC-Alu blisters at 75 mg, 150 mg, and 300 mg strengths as hard gelatin or HPMC capsules.

For oral unit-dose granules, the decision to wet-granulate rather than dry-blend is driven by segregation velocity in vertical form-fill-seal hoppers and not by dissolution alone. Formulations registered as carbasalate calcium 500 mg or 1000 mg sachets typically use 70–85 wt% API, 2–5 wt% povidone K30 as binder, 10–20 wt% mannitol or sorbitol as water-soluble diluent, 0.2–0.5 wt% sodium saccharin, and 0.5–1.5 wt% flavoring agent, balanced to 100 wt%; the granulation liquid is purified water or an ethanol-water mixture, and the endpoint is controlled by loss on drying at 1.0–2.5 %. In a Glatt GPCG 60 top-spray fluid bed, inlet air temperature is held at 60–80 °C with product temperature at 25–35 °C, spray rate at 100–300 g/min, and atomizing air pressure at 2–4 bar; granule fraction below 75 µm is kept under 15 % to prevent blocking of dosing augers. Powder flow and particle-size distribution are verified against Ph. Eur. 2.9.36 and Ph. Eur. 2.9.12, dissolution against Ph. Eur. 2.9.3, and elemental impurity limits under ICH Q3D. The finished granules are filled on horizontal sachet machines with heat-sealed foil laminate at a residual oxygen level below 5 %; finished sachets contain oral granules for solution or suspension at 500 mg and 1000 mg carbasalate calcium per unit dose.

Injectable Aqueous Solution Stability and Endotoxin Control

Aseptic fill-finish lines for carbasalate calcium injectable solutions operate under EU GMP Annex 1 and USP <1> because acetylsalicylic ester hydrolysis prevents terminal steam sterilization; production therefore requires a filtered, depyrogenated aqueous vehicle and an isolator or restricted-access barrier system. Solution formulations are compounded at 100–200 mg/mL carbasalate calcium, pH adjusted to 5.8–6.3 with dilute sodium hydroxide, and osmolality maintained at 280–320 mOsm/kg with sodium chloride or mannitol; lyophilized presentations are filled to 250–1000 mg per vial, with a freeze-drying cycle that freezes the solution to -40 °C, primary-dries at -10 °C under 0.2 mbar for 24–48 h, and secondary-dries at 25 °C under 0.05 mbar until residual moisture is below 1.0 %. The fill line uses 0.22 µm polyethersulfone filters, nitrogen overlay to reduce headspace oxygen, and fluoropolymer-coated rubber closures; closure elastomer compatibility is evaluated because leachable-mediated hydrolysis is a known parenteral stability variable. Parenteral compendial compliance is demonstrated through USP <85> and Ph. Eur. 2.6.14 for bacterial endotoxins, USP <788> and Ph. Eur. 2.9.19 for particulate matter, USP <790> for visible particulates, and ICH Q1A for photostability and accelerated stability. Sterile vials and ampoules constitute powder for solution for injection at 1000 mg per vial and ready-to-use solution for injection at 100 mg/mL, intended for intravenous or intramuscular administration where the marketing authorization permits.

Carbon Dioxide Generation Is Not the Only Process Variable in Effervescent Carbasalate Calcium Tablets

Because the sodium bicarbonate and citric acid reaction delivers rapid disintegration but also generates free water during granulation, effervescent carbasalate calcium tablets require separate acid and basic granulation. The registered effervescent matrix contains 250–1000 mg carbasalate calcium per tablet, with sodium bicarbonate at 20–35 wt%, anhydrous citric acid at 15–25 wt%, mannitol or sorbitol at 10–20 wt%, polyethylene glycol 6000 at 1–3 wt% as a lubricant and anti-caking agent, and sodium lauryl sulfate at 0.1–0.5 wt% to lower surface tension during re-dissolution; the balance is carbasalate calcium and minor flavoring agents. Because wet granulation with water is incompatible with carbasalate calcium, the acid and basic phases are granulated separately with anhydrous ethanol or compacted by roller compaction; final blending is performed at relative humidity below 25 %, and the blend is compressed at 10–20 kN to a hardness of 40–70 N. Disintegration is tested according to USP <701> and Ph. Eur. 2.9.1, with an acceptance window of complete disintegration within 300 s at 15–25 °C; residual water is controlled by Karl Fischer titration below 0.5 %, and packaging must be aluminum/PVDC laminate with desiccant because moisture ingress above 0.5 % initiates pre-release gas evolution and tablet cracking. Published data for the exact hydrolysis rate of carbasalate calcium in this specific granulation configuration is limited; development batches therefore establish the maximum allowable granulation moisture empirically rather than by extrapolation from aspirin monographs. The final effervescent tablets and effervescent granules are reconstituted in aqueous solution for oral administration at 600 mg and 1000 mg carbasalate calcium per dose.

When Drinking-Water Powders Are Diluted Under Cold-Chain Farm Conditions

On pig and poultry farms, veterinary-grade carbasalate calcium powders are administered through drinking-water lines after dilution at ambient temperature; the acceptance criterion for field use is therefore a clear solution at 5–10 °C within 5 minutes and no precipitate or salicylic acid haze after 24 hours. Water-soluble powder formulations registered under EU Regulation 2019/6 and supported by VICH GL11 and VICH GL18 are typically blended with 60–75 wt% carbasalate calcium, 15–25 wt% citrate-phosphate or citrate-citric acid buffer salts to hold solution pH between 4.5 and 5.5, and 5–15 wt% maltodextrin or anhydrous glucose as carrier; the exact registered composition varies by marketing authorization, and the labeled in-use dilution is not a fixed ratio but is based on milligrams per kilogram body weight for the target species. Production uses a ribbon blender with a working capacity of 500–1000 kg, multiple blending cycles of 15–25 minutes, and a 0.5 mm security sieve before filling into foil-lined 1 kg, 5 kg, or 10 kg sachets. Particle-size distribution is controlled by Ph. Eur. 2.9.12, powder flow by Ph. Eur. 2.9.36, residual solvents by VICH GL18 and ICH Q3C, and elemental impurities by ICH Q3D. The packed sachets are veterinary oral water-soluble granules or powders for swine and poultry, intended for reconstitution through medicator pumps or bulk tanks; water-line flow rates of 1–10 L/min in farrowing or broiler houses require that complete dissolution and filterability are retained across the full in-use concentration range.